RATIONALE: The mitochondrial ATP sensitive potassium channel (mK(ATP)) is implicated in cardioprotection by ischemic preconditioning (IPC), but the molecular identity of the channel remains controversial. The validity of current methods to assay mK(ATP) activity is disputed. OBJECTIVE: We sought to develop novel methods to assay mK(ATP) activity and its regulation. METHODS AND RESULTS: Using a thallium (Tl(+))-sensitive fluorophore, we developed a novel Tl(+) flux based assay for mK(ATP) activity, and used this assay probe several aspects of mK(ATP) function. The following key observations were made. (1) Time-dependent run down of mK(ATP) activity was reversed by phosphatidylinositol-4,5-bisphosphate (PIP(2)). (2) Dose responses of mK(ATP) to nucleotides revealed a UDP EC(50) of approximately 20 micromol/L and an ATP IC(50) of approximately 5 micromol/L. (3) The antidepressant fluoxetine (Prozac) inhibited mK(ATP) (IC(50)=2.4 micromol/L). Fluoxetine also blocked cardioprotection triggered by IPC, but did not block protection triggered by a mK(ATP)-independent stimulus. The related antidepressant zimelidine was without effect on either mK(ATP) or IPC. CONCLUSIONS: The Tl(+) flux mK(ATP) assay was validated by correlation with a classical mK(ATP) channel osmotic swelling assay (R(2)=0.855). The pharmacological profile of mK(ATP) (response to ATP, UDP, PIP(2), and fluoxetine) is consistent with that of an inward rectifying K(+) channel (K(IR)) and is somewhat closer to that of the K(IR)6.2 than the K(IR)6.1 isoform. The effect of fluoxetine on mK(ATP)-dependent cardioprotection has implications for the growing use of antidepressants in patients who may benefit from preconditioning.
RATIONALE: The mitochondrial ATP sensitive potassium channel (mK(ATP)) is implicated in cardioprotection by ischemic preconditioning (IPC), but the molecular identity of the channel remains controversial. The validity of current methods to assay mK(ATP) activity is disputed. OBJECTIVE: We sought to develop novel methods to assay mK(ATP) activity and its regulation. METHODS AND RESULTS: Using a thallium (Tl(+))-sensitive fluorophore, we developed a novel Tl(+) flux based assay for mK(ATP) activity, and used this assay probe several aspects of mK(ATP) function. The following key observations were made. (1) Time-dependent run down of mK(ATP) activity was reversed by phosphatidylinositol-4,5-bisphosphate (PIP(2)). (2) Dose responses of mK(ATP) to nucleotides revealed a UDP EC(50) of approximately 20 micromol/L and an ATP IC(50) of approximately 5 micromol/L. (3) The antidepressant fluoxetine (Prozac) inhibited mK(ATP) (IC(50)=2.4 micromol/L). Fluoxetine also blocked cardioprotection triggered by IPC, but did not block protection triggered by a mK(ATP)-independent stimulus. The related antidepressant zimelidine was without effect on either mK(ATP) or IPC. CONCLUSIONS: The Tl(+) flux mK(ATP) assay was validated by correlation with a classical mK(ATP) channel osmotic swelling assay (R(2)=0.855). The pharmacological profile of mK(ATP) (response to ATP, UDP, PIP(2), and fluoxetine) is consistent with that of an inward rectifying K(+) channel (K(IR)) and is somewhat closer to that of the K(IR)6.2 than the K(IR)6.1 isoform. The effect of fluoxetine on mK(ATP)-dependent cardioprotection has implications for the growing use of antidepressants in patients who may benefit from preconditioning.
Authors: Bin Ye; Stacie L Kroboth; Jie-Lin Pu; Jason J Sims; Nitin T Aggarwal; Elizabeth M McNally; Jonathan C Makielski; Nian-Qing Shi Journal: Circ Res Date: 2009-10-01 Impact factor: 17.367
Authors: Bruno B Queliconi; Andrew P Wojtovich; Sergiy M Nadtochiy; Alicia J Kowaltowski; Paul S Brookes Journal: Biochim Biophys Acta Date: 2010-11-20
Authors: Sergey M Korotkov; Irina V Brailovskaya; Anton R Shumakov; Larisa V Emelyanova Journal: J Bioenerg Biomembr Date: 2015-04-14 Impact factor: 2.945
Authors: D Brian Foster; Alice S Ho; Jasma Rucker; Anders O Garlid; Ling Chen; Agnieszka Sidor; Keith D Garlid; Brian O'Rourke Journal: Circ Res Date: 2012-07-17 Impact factor: 17.367
Authors: Prasad V G Katakam; Edina A Wappler; Paige S Katz; Ibolya Rutkai; Adam Institoris; Ferenc Domoki; Tamás Gáspár; Samuel M Grovenburg; James A Snipes; David W Busija Journal: Arterioscler Thromb Vasc Biol Date: 2013-01-17 Impact factor: 8.311
Authors: Andrew P Wojtovich; William R Urciuoli; Shampa Chatterjee; Aron B Fisher; Keith Nehrke; Paul S Brookes Journal: Am J Physiol Heart Circ Physiol Date: 2013-04-12 Impact factor: 4.733